Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
Analysts' Top Healthcare Picks: Lifecore Biomedical (LFCR), Castle Biosciences (CSTL)
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $42
Canaccord Genuity Sticks to Its Buy Rating for Castle Biosciences (CSTL)
Castle Biosciences Is Maintained at Sector Outperform by Scotiabank
Castle Biosciences Analyst Ratings
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44
Strong Growth Prospects and Financial Health Support Buy Rating for Castle Biosciences
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $45
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $40
Castle Biosciences (CSTL) Gets a Buy From Lake Street
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $42
Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39
Castle Biosciences Is Maintained at Outperform by Baird
Castle Biosciences Analyst Ratings
KeyBanc Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $36
Castle Biosciences Is Maintained at Buy by Canaccord Genuity
Castle Biosciences Analyst Ratings
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $42
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $34